Navigation Links
Sale of Colon Cancer Diagnostic Tool to Czech Republic
Date:4/30/2008

SAN DIEGO, April 30 /PRNewswire-FirstCall/ -- SpectraScience, Inc. (OTC Bulletin Board: SCIE), a San Diego based medical device company, today announced that it has sold one of its WavSTAT(R) Optical Biopsy Systems to the Almeda Company of Prague, Czech Republic. The device will be used at the University of Prague during colonoscopy to determine if tissue is normal, pre-cancerous or cancer.

Generally, doctors search for polyps, which are abnormal growths that stick out from the colon lining and can turn into cancer. However, another type of growth is much more dangerous and harder to see because it is flat or depressed and similar in color to healthy tissue. The WavSTAT uses an optical probe in conjunction with a colonoscope to determine within seconds if these flat or depressed lesions are cancerous or pre-cancer with greater than 96% accuracy.

Michel Vaudry, SpectraScience's Director of International Sales said, "The Czech Republic has one of the highest instances of colorectal cancer in the world. Our Czech partner, the Almeda Company, sees a large opportunity in helping physicians detect these flat 'polyps' at an early stage. In a recent study, it was found that close to 10% of patients had flat lesions, and that these lesions were five times as likely as polyps to contain cancerous or precancerous tissue. The flat or depressed lesions accounted for 15 percent of the potentially cancerous growths found in the study, but were involved in half of the cancers."

Vaudry continued, "The feeling amongst physicians that we have spoken with in the Czech Republic is that the WavSTAT is a wonderful adjunctive tool to aid in early detection of these flat lesions. We are now exploring additions to our export team in other European countries such as Italy, Germany and France."

This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements involve risks and uncertainties that may cause SpectraScience's actual results to differ materially from results discussed in forward-looking statements. Readers are urged to carefully review and consider the various disclosures made by SpectraScience in this news release, its most recent Form 10-KSB and in SpectraScience's other reports filed with the Securities and Exchange Commission ("SEC") that attempt to advise interested parties of the risks and factors that may affect SpectraScience's business. These forward- looking statements are qualified in their entirety by the cautions and risk factors filed by SpectraScience in its annual report on Form 10-KSB and other documents.

About SpectraScience, Inc.

SpectraScience is a San Diego based medical device company that designs, develops, manufactures and markets spectrophotometry systems capable of determining whether tissue is normal, pre-cancerous or cancerous without physically removing tissue from the body. The WavSTAT Optical Biopsy System uses light to optically scan tissue and provides the physician with an immediate analysis. With FDA approval for sale in the U.S. and the CE Mark for the European Union, the WavSTAT System is the first commercially available product that incorporates this innovative technology for clinical use. The Company's LUMA(R) cervical imaging technology has received FDA approval as an optical non-invasive system that is proven to more effectively detect cervical cancer precursors than conventional methods available in the market today.

Contact:

SpectraScience, Inc.

Jim Hitchin, Chief Executive Officer

(858) 847-0200 x201

http://www.spectrascience.com

Hayden Communications

Investor Relations

Todd Pitcher

(858) 518-1387


'/>"/>
SOURCE SpectraScience, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Medicsight Announces Chinese State Food and Drug Administration Approval for MedicRead Colon Workstation
2. Colon Cancer Screening Laws Now Cover Half of U.S. Population
3. Medicsight Welcomes U.S. Initiative to Reimburse CT Colonography for Early Detection of Colorectal Cancer
4. GeneNews initiates patient sample accrual for validation studies of colon cancer blood test
5. Agencourt Genomic Services is Key Collaborator in New Research That Further Defines Landscape of Breast and Colon Cancers
6. Results of Colon Cancer Study Utilizing Pressure Cycling Technology (PCT) Presented at the American College of Gastroenterology Annual Scientific Meeting
7. Aflac and the American Association for Cancer Research Unite to Issue Inaugural Aflac Career Development Award for Childhood Cancer Research
8. deCODE Discovers Fourth Major Set of Common Genetic Variants Linked to Risk of Estrogen Receptor-Positive Breast Cancer
9. One4One Campaign to Raise $1 Million to Improve Cervical Cancer Education and Resources
10. Avastin Used in Combination with Drugs from Bristol-Myers Squibb Has Advantages in Survival Rates Over the Current Sales-Leading Therapy for Advanced Ovarian Cancer
11. Quest PharmaTech Receives Support from National Research Councils Industrial Research Assistance Program (NRC-IRAP) to develop Ultrasound Technology for the Treatment of Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2016)... Nov. 30, 2016  The Allen Institute for ... the first publicly available collection of gene edited, ... target key cellular structures with unprecedented clarity. Distributed ... powerful tools are a crucial first step toward ... understand what makes human cells healthy and what ...
(Date:11/30/2016)... , Nov. 30, 2016  Tempus, a ... cancer care, and Penn,s Abramson Cancer Center have ... a positive response to immunotherapy treatment based on ... As part of a research collaboration, Tempus ... and melanoma cancer patient data to Penn. Utilizing ...
(Date:11/30/2016)... , 30. November 2016   Merck ... heute die Unterzeichnung einer Reihe von Vereinbarungen ... wird Evotec AG Screeningleistungen für Mercks Palette ... Der Zugriff auf diese Bibliotheken in Kombination ... einen schnelleren Weg zur Ermittlung und Erforschung ...
(Date:11/30/2016)... --  Merck , a leading science and technology company, ... of agreements with Evotec AG, whereby Evotec AG will ... such as CRISPR and shRNA libraries. Combining access to ... pathway to explore and identify new drug targets. ... targets, a process that can be time- and labor-intensive," ...
Breaking Biology Technology:
(Date:11/22/2016)... MINNETONKA, Minn. , Nov. 22, 2016   ... that supports the entire spectrum of clinical research, is ... by Medical LiveWire Healthcare and Life Sciences Awards ... This award caps off an unprecedented year of recognition ... clinical trials for over 15 years. iMedNet ...
(Date:11/16/2016)... , Nov. 16, 2016 Sensory Inc ... and security for consumer electronics, and VeriTran ... and retail industry, today announced a global partnership ... way to authenticate users of mobile banking and ... TrulySecure™ software which requires no specialized biometric ...
(Date:6/27/2016)... 27, 2016 Research and Markets has announced ... report to their offering. ... to grow at a CAGR of 12.28% during the ... on an in-depth market analysis with inputs from industry experts. The ... coming years. The report also includes a discussion of the key ...
Breaking Biology News(10 mins):